FDA
-
-
-
-
-
-
-
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
-
-
-
-
-
-
-
NextCure Announces Acceptance of IND Application for LNCB74
-
-
-
-
-
-
-
NextCure Provides Update and Reports Third Quarter 2022 Financial Results
-
-
-
-
-
-
-
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
-
-
-
-
-
-
-
NextCure Reports First Quarter 2020 Financial Results
-
-
-
-
-
-
-
NextCure Reports Third Quarter 2019 Financial Results
-
325,873 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

